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Abstract
Background: Biochemical control of GH/IGF-I excess in acromegaly (ACRO) is associated 
with persistent impairment of trabecular microstructure leading to increased risk 
of vertebral fractures. Circulating miRNAs modulate the activity of osteoblasts and 
osteoclasts, and may be potential biomarkers of osteoporosis.
Aims: Identify differentially expressed miRNAs in the serum of patients with controlled 
ACRO vs controls and correlate miRNA levels with both biochemical and structural bone 
parameters.
Patients and methods: Twenty-seven patients with controlled ACRO (11 males, 16 females; 
mean age, 48 ± 5 years; BMI, 28 ± 4 kg/m2) and 27 age-, gender- and BMI-matched 
controls were recruited. Areal BMD at lumbar spine and femur, and trabecular bone 
score were assessed; volumetric BMD was measured by quantitative computed 
tomography QCT-Pro (Mindways). Twenty miRNAs, chosen by their putative role in bone, 
were quantified in serum using real-time qPCR.
Results: In ACRO patients, miR-103a-3p and miR-191-5p were found overexpressed, 
whereas miR-660-5p was underexpressed (P < 0.001). miR-103a-3p levels were negatively 
associated with both trabecular vBMD at trochanter and serum osteoprotegerin 
concentrations (P < 0.05) and positively with vitamin D concentrations (P < 0.01) and total 
cross-sectional area of the femoral neck (P < 0.05). miR-660-5p levels were correlated 
with both trabecular vBMD at trochanter and OPG concentrations (P < 0.05), but were 
negatively associated with vitamin D levels (P < 0.05). A negative correlation between 
miR-103-a-3p and miR-660-5p was found in both groups (P < 0.001).
Conclusions: Circulating miR-103a-3p and miR-660-5p are differentially expressed in 
controlled ACRO patients and associated with bone structural parameters. miRNAs may be 
one of the mechanisms involved in the pathogenesis of bone disease and could be used as 
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Growth hormone (GH) and insulin-like growth factor-I 
(IGF1) are anabolic hormones which influence bone 
metabolism through the modulation of several signaling 
pathways (1). In vitro studies showed that GH enhances 
the proliferation and differentiation of osteoblastic cell 
lines driving the commitment of the mesenchymal stem 
cell (MSC) to the osteoblastogenesis (1, 2, 3). On the other 
hand, IGF1 enhances the function of mature osteoblasts 
and maintains appropriate levels of bone matrix and bone 
mass (1).
Acromegaly (ACRO) is a rare disease caused by 
excessive GH production from a pituitary adenoma (4). 
Chronic elevation of GH and IGF1 in ACRO is associated 
with severe cardiovascular, respiratory and metabolic 
complications, which lead to an average 10-year reduction 
of life expectancy and a double standardized mortality 
rate as compared with the general population (5). Bone 
abnormalities are also a frequent manifestation of ACRO 
due to the deleterious effects of GH excess on bone 
remodeling and calcium homeostasis (1).
ACRO patients show increased bone turnover and 
deterioration of both biomechanical competence and 
microarchitecture at the trabecular compartment (3, 6, 7). 
Of note, the latter has been associated with an increased 
prevalence of vertebral fractures even in the controlled 
patients, in the presence of normal lumbar areal bone 
mineral density (aBMD) (7). Cortical bone also appears 
to be impaired, in that a decrease in both bone material 
strength index (a marker of cortical bone properties), as 
assessed using microindentation, and femoral cortical 
volumetric bone mineral density (vBMD) have been 
described in ACRO patients despite biochemical control 
of the disease (8, 9).
miRNAs are single-strand, non-coding RNAs that 
span between 19 and 24 nucleotide bases (10). These 
molecules are involved in the modulation of a wide 
variety of biological processes, including bone cell 
formation, bone remodeling, bone homeostasis and 
skeletal development (10). In particular, subsets of 
miRNAs influence the commitment and differentiation 
of the MSC into the osteogenic lineage by regulating 
several molecular pathways (11). Indeed, the deregulation 
of miRNA-mediated mechanisms has been described as 
an important pathogenic factor for bone degeneration 
and skeletal disease (11). Interestingly, miRNAs also 
circulate in serum as extracellular nuclease-resistant 
entities through a variety of carriers, such as exosomes, 
apoptotic bodies and vesicle-free lipoprotein (12). 
As a result, miRNAs have been advocated as promising 
biomarkers to predict onset and progression of chronic 
disease, including osteoporosis (13). Different levels of 
circulating miRNAs (‘signatures’) have been found in 
patients with both idiopathic (10) and postmenopausal 
osteoporosis (10, 14, 15, 16) and have been indicated as 
reliable predictors of fragility fractures in postmenopausal 
women with and without type 2 diabetes (10, 17, 
18, 19, 20, 21). Belaya et  al. recently analyzed bone 
samples from patients with active ACRO and found 
significant changes in the expression of several miRNAs 
involved in osteoblastogenesis (22). However, whether 
some circulating miRNAs are associated with bone 
abnormalities in ACRO and, therefore, could represent 
useful markers to predict persistent bone impairment in 
these patients is still to be determined.
Thus, our cross-sectional study was aimed at 
evaluating if there are differentially expressed miRNAs in 
the serum of patients with controlled ACRO as compared 
with sex-, age- and BMI-matched healthy controls. In 
addition, we examined if these differentially expressed 
miRNAs are related to bone parameters in our patients, 
including bone turnover markers, vBMD at spine and 
femur and trabecular bone score (TBS), a tool designed to 




We studied 27 patients (16 females and 11 males) with 
controlled ACRO who have been recruited successively 
while attending our clinic. Eighteen of these patients 
(66%) had been evaluated in previous studies from our 
center (8, 23).
Controlled ACRO was defined as IGF1 concentrations 
within the specific age-adjusted reference range, and in 
those patients who were not on GH receptor antagonist, 
random GH concentrations were lower than 1 ng/mL. 
When the 75 g oral glucose load test was performed, 
the GH value equal to or <0.4 ng/mL were considered 
suggestive of cured disease (24). All had a GH-secreting 
pituitary tumor confirmed pathologically.
Five patients were on pharmacological treatment: 
three on somatostatin analogs (SSa) and the other two were 
on combination therapy with a SSa and either cabergoline 
or pegvisomant. All patients had transsphenoidal surgery 
from 6 months to 25 years (median: 5 years) prior to the 
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inclusion in the study, and seven of them also received 
radiotherapy from 7 to 24 years (median: 16 years) after 
unsuccessful surgery. Three patients had secondary adrenal 
insufficiency, and all of them were on stable replacement 
dose of hydrocortisone. Five patients had secondary 
hypothyroidism and were on stable replacement therapy 
with levothyroxine at the time of the study. Four males 
had secondary hypogonadism. Because all of them were 
on stable testosterone replacement for more than 1 year, 
they were considered eugonadal. Nine women had 
regular menses and seven were postmenopausal. None 
of the patients had GH deficiency, diagnosed when IGF-I 
levels were below two standard deviations for the age-
sex normal range in a patient with at least three other 
documented hormone deficiencies or with a peak plasma 
GH less than 3 μg/L during and insulin tolerance test 
(ITT) (25).
Mean (±s.d.) duration of disease was 164 ± 119 months 
and was estimated as the time elapsed between the onset 
of symptoms and signs of ACRO (evaluated through old 
photographs and clinical history) and the time when 
treatment was proven to be effective. Mean (±s.d.) duration 
of control was 146 ± 121 months and was calculated from 
the time between hormone normalization and study 
entry.
Twenty-seven age-, gender- and BMI-matched controls 
were also studied, recruited through advertisements at the 
blood donor center of our Hospital.
Control subjects who reported fragility fractures or 
who had morphometric vertebral fractures of any grade 
were excluded from the study. A fragility fracture was 
defined as any low-energy fracture, excluding those of the 
hands, feet and skull.
Patients and controls with malignancies, inflammatory 
disorders, kidney or liver dysfunctions were also excluded 
from the study.
Consent has been obtained from each patient or 
subject after full explanation of the purpose and nature of 
all procedures used.
This study was approved by the Ethical Committee of 
our institution (CEIC-IIB SantPau).
Biochemical measurements
Serum IGF1 concentrations were measured by an enzyme 
immunoassay (Mediagnost, Reutlingen/Germany) 
with a sensitivity of 0.09 ng/mL. The intra- and inter-
assay coefficients of variation (CVs) were 6.7 and 6.8%, 
respectively. In the study, IGF-I is expressed as SD 
score (SDS).
Growth hormone (GH), osteocalcin, carboxy-
terminal collagen crosslinks (CTx) and total procollagen 
type 1 amino-terminal propeptide (P1NP) were measured 
by electrochemiluminescent immunoassay (cobas e601; 
Roche Diagnostics GmbHm). Imprecision for mean 
GH values between 0.18 and 35 μg/L was 3–3.4%, for 
osteocalcin concentrations between 6.11 and 160 μg/L 
was 2–2.3%, for β-crosslaps concentrations between 0.06 
and 4.64 μg/L was 5.7–2.4% and for total P1NP values 
between 14.4 and 1090 μg/L was 3.7–3.4%. Sensitivity 
was 0.05 μg/L for GH, 0.5 μg/L for osteocalcin, 0.01 μg/L 
for CTx and 5 μg/L for P1NP. Serum 25-hydroxyvitamin 
D (vitamin D) concentrations were determined using 
an enzyme immunoassay (IDS, Boldon, UK), with a 
sensitivity of 4.8 ng/mL. Imprecision for mean vitamin D 
values between 12 and 77.9 ng/mL was 9.9–7.7%.
Serum PTH concentrations were measured by 
electrochemiluminescent immunoassay (cobas e601; 
Roche Diagnostics GmbHm). Imprecision for mean PTH 
values between 23.2 and 184 pg/mL was 3.4–1.7%. Serum 
osteoprotegerin (OPG) concentrations were measured 
by an enzyme-linked immune-sorbent assay (Abcam), 
with a sensitivity <1 pg/mL and range between 1.23 and 
900 pg/mL.
Both serum Dickkopf-related protein 1 (DKK1) and 
sclerostin (SOST) concentrations were measured using 
an enzyme immunoassay (Biomedica, Vienna, Austria). 
Both intra- and inter-assay CVs for DKK1 were 3% 
and the sensitivity was 1.7 pmol/L. Intra- and inter-
assay CVs for SOST were <7 and <10%, respectively; 
sensitivity was 3.2 pmol/L. Serum osteoprotegerin 
concentrations were measured using an enzyme-
linked immune-sorbent assay (Biomedica). Intra- and 
interassay CVs were <3 and <5%, respectively; sensitivity 
was 0.07 pmol/L.
Radiological imaging
Areal BMD (aBMD) was measured by dual-energy X-ray 
absorptiometry scanning (Hologic Discovery DXA 
system, HOLOGIC, Bedford, MA, USA). The CV was 1%. 
Patients had the lumbar spine and femoral neck scanned. 
The scan acquisition and analysis were performed 
by a certified and experimented technician and were 
performed according to the ISCD standards. (http://www.
iscd.org/documents/2015/06/2015-iscd-adult-official-
positions.pdf).
Trabecular bone score was acquired from the lumbar 
spine DXA image automatically by the TBS iNsight 
software, Medimaps Group SA, Geneva, Switzerland.
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-18-0482
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd





Quantitative computed tomography (QCT) was 
performed using a Phillips Brilliance 16 scanner. 
Participants were positioned supine on the scanner table, 
lying on top of a solid calibration phantom which covered 
levels L2–L4 (Mindways Software, Inc. Austin, TX, USA). 
Spine volumetric BMD was calculated as the mean of 
the values at L2, L3 and L4 (expressed as LS vBMD). To 
measure femoral vBMD, all the scans were acquired from 
the acetabulum directly above the femoral head down 
to 1 cm below the lesser trochanter, resulting in 25–35 
slices, with 3 mm slice thickness, over a range of 8–12 cm. 
All scans were performed at 120 kV and 70 to 200 mAs 
depending on height and weight of the patient, according 
to the Mindways technical specifications. The images were 
processed and analyzed using QCT-pro Software version 
4.1.3 and the QCT-pro Bone Investigational Toolkit 
Version 2.0 (BIT, Mindways Software, Inc.) by the same 
physician (JM). Volumetric BMD was obtained from the 
hip QCT analysis performing the following automated 
steps: (a) extraction of the proximal femur and (b) rotation 
and segmentation of bone voxels from soft tissue in three 
planes (axial, sagittal and coronal). For each scan at each 
time point, a fixed threshold (450 mg/cm3) was used 
to discriminate cortical from trabecular compartment 
(26). Mechanical properties were obtained using the 
BIT software. A sliced narrow neck (NN) analysis was 
performed and the mechanical properties (buckling ratio 
(BR), cross-sectional area (CSA; cm2) and average cortical 
thickness (ACT, cm)) were the mean value of the NN series 
results. NN consists of nine slices of the femoral neck; the 
average of the slice structural results was used to perform 
the analysis.
miRNA isolation from serum samples
RNA extraction was conducted at Exiqon Services, 
Denmark. Serum samples were centrifuged at 3000 g 
for 5 min at 4°C. An aliquot of 200 μL per sample was 
transferred to a FluidX tube and 60 μL of Lysis solution 
BF containing 1 μg carrier-RNA per 60 μL Lysis Solution 
BF and RNA spike-in template mixture was added to the 
sample and mixed for 1 min and incubated for 7 min at 
room temperature, followed by addition of 20 μL Protein 
Precipitation solution BF. Total RNA was extracted from 
the samples using miRCURY RNA isolation kit – Biofluids; 
high-throughput bead-based protocol v.1 (Exiqon, 
Vedbaek, Denmark) in an automated 96-well format. The 
purified total RNA was eluted in a final volume of 50 μL. 
The RNA was stored in a −80°C freezer.
miRNA selection
Since very little information on miRNAs in GH excess 
is available, the selection of miRNAs to be measured 
in this study was based on previously published data 
evaluating the relationship between miRNAs and bone 
phenotypes (19, 21, 27, 28). miR-99a-5p, miR-125a-5p, 
miR-885-5p, miR-324-5p, miR-335-3p, miR-7-1-3p, 
miR-22-3p, miR-660-5p and miR-10b-5p were selected 
based on a preliminary screening, which was performed 
in six patients and six controls using miRCURY LNATM 
Universal RT microRNA PCR Serum/Plasma Focus 
panel (Exiqon) (Supplementary Table  1, see section on 
supplementary data given at the end of this article). 
miR-451a and miR-23a-3p were included for hemolysis 
assessment of samples.
MicroRNA real-time qPCR
miRNA qPCR and further data analyses were conducted 
at Exiqon Services, Denmark. Using the miRCURY 
LNA Universal RT microRNA PCR, Polyadenylation 
and cDNA synthesis kit (Exiqon), 2 μL RNA was reverse 
transcribed in 10 μL reactions. Then, cDNA was diluted 
50× and assayed in 10 μL PCR reactions according to 
the protocol for miRCURY LNA Universal RT microRNA 
PCR; each microRNA was assayed once by qPCR on 
the microRNA Ready-to-Use PCR, Custom Pick and 
Mix panel using ExiLENT SYBR Green master mix. 
Negative controls excluding template from the reverse 
transcription reaction was performed and profiled like 
the samples. The amplification was performed in a 
LightCycler 480 Real-Time PCR System (Roche) in 384-
well plates. The amplification curves were analyzed 
using the Roche LC software, both for determination 
of Cq (by the 2nd derivative method) and for melting 
curve analysis.
The amplification efficiency was calculated using 
algorithms similar to the LinReg software. All assays were 
inspected for distinct melting curves and the Tm was 
checked to be within known specifications for the assay. 
Furthermore, assays must be detected with five Cqs less 
than the negative control, and with Cq <37 to be included 
in the data analysis. Data that did not pass these criteria 
were omitted from any further analysis. Cq was calculated 
as the 2nd derivative.
Using NormFinder the best normalizer was found to be 
the average of assays detected in all samples. All data were 
normalized to the average of assays detected in all samples 
(average–assay Cq). Data quality control, unsupervised 
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data analysis and Student t-test with Benjamini–Hochberg 
correction were performed (corrected P values <0.05 were 
accepted as significant).
Hemolysis assessment
MicroRNA contamination from hemolysis (29) was 
assessed using miR-451 (expressed in red blood cells) and 
the miRNA relatively stable in serum, miR-23a. The ratio 
between these two microRNAs correlates to degree of 
hemolysis. Samples with ratios above 7.0 are considered 
as affected by hemolysis.
Statistical analysis
The data are expressed as the mean ± s.d., except for data 
that were not normally distributed, in which case median 
values and ranges are reported. Comparisons between 
two groups were performed using Student’s t (Gaussian 
distribution) and Mann–Whitney’s U (non-Gaussian 
distribution) tests, depending on the data distribution. 
Correlations were assessed using the Pearson’s correlation 
coefficient or Spearman rank order depending on whether 
the data were normally distributed. Correlations were 
adjusted for age, sex, BMI and gonadal status by a stepwise 
multiple linear regression analysis. Tests were two-tailed, 
and a P < 0.05 was considered significant.
Results
Clinical characteristics and bone parameters
The characteristics of the study population are shown in 
Table 1.
Volumetric bone mineral density at lumbar spine 
(LSvBMD), as assessed by QCT, was lower in ACRO 
patients as compared with healthy controls (106 ± 39 vs 
129 ± 30 mg/cm3; P = 0.040). A reduction of cortical vBMD 
was also found in ACRO patients as compared with controls 
at the level of the total hip (831 ± 57 vs 883 ± 65 mg/cm3; 
P = 0.014), femoral neck (817 ± 90 vs 902 ± 159 mg/cm3; 
P = 0.037) and trochanter (742 (86) vs 848 (204) mg/cm3; 
P = 0.006). CSA at the proximal femur was greater in ACRO 
than controls (9.9 ± 2 vs 8 ± 2 cm2, P = 0.031).
When postmenopausal women were ruled out from 
the analysis, cortical vBMD at total hip and trochanter 
were still reduced in ACRO patients as compared 
with their healthy, eugonadal counterpart (total hip, 
125 ± 17 vs 142 ± 25 mg/cm3, P = 0.005; trochanter, 
727 (87) vs 809 (228) mg/cm3; P = 0.012). When only 
postmenopausal women were compared, no differences 
in bone parameters were found.
Osteoprotegerin and DKK1 levels were significantly 
higher in ACRO as compared with controls (4.6 ± 1.5 
vs 3.9 ± 0.8 pmol/L, P = 0.047 for osteoprotegerin; 
35 ± 15 pmol/L vs 25  ± 14 pmol/L, P = 0.011 for DKK1).
Differentially expressed microRNAs ACRO vs controls
The hemolysis assessment of the samples showed no sign 
of red blood cell contamination. When comparing the 
ACRO group to the control group, the following miRNAs 
were found to be differentially expressed: miR-103a-3p 
and miR-191-5p were overexpressed in ACRO patients, 
whereas miR 660-5p and miR-25-3p were underexpressed 
in ACRO patients. miR-25-3p did not pass the Benjamini–
Hochberg correction (Table 2).
Relationship between serum miRNAs and 
bone parameters
Significant correlations between differentially expressed 
miRNAs and bone parameters in ACRO patients are 
shown in Table  3. miR-103a-3p levels were negatively 
associated with both trabecular vBMD at trochanter 
(r −0.38, P = 0.047) and serum OPG concentrations 
(r −0.41, P = 0.032). Levels of miR-103a-3p were also 
positively associated with vitamin D concentrations 
(r 0.54, P = 0.003) and total CSA (Spearman’s rho 0.43, 
P = 0.045). In contrast, levels of miR-660-5p were 
positively correlated with both trabecular vBMD at 
trochanter (r 0.38, P = 0.047) and OPG concentrations 
(r 0.47, P = 0.012), but were negatively associated 
with vitamin D levels (r −0.44, P = 0.022). Levels of 
miR-25-3p were positively correlated with osteocalcin 
concentrations (r 0.38, P = 0.047).
In controls (Table  4), miR-103a-3p levels were 
positively associated with CTx concentrations (r 0.45, 
P = 0.017) and TBS (r 0.51, P = 0.006), and miR-660-5p 
levels were negatively associated with TBS (r −0.43, 
P = 0.023). Levels of miR-25-3p were negatively associated 
with lumbar spine aBMD (r −0.43, P = 0.030).
No correlations were detected between miR-191-5p 
and bone parameters.
miR-103-a-3p was negatively associated with 
miR-660-5p in both ACRO patients (r −0.86, P < 0.001) 
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and controls (r −0.70, P < 0.001). In controls only, 
miR-191-5p was negatively associated with miR-25-3p 
(r −0.80, P < 0.001).
No correlations were found between any of the 
miRNAs analyzed and the duration of either active or 
controlled disease.
Discussion
We have demonstrated that levels of circulating 
miR-103-a-3p, miR-660-5p and miR-191-5p are 
differentially expressed in serum of patients with 
controlled acromegaly (ACRO) as compared with 
Table 1 General, biochemical and bone characteristics of 27 patients with controlled acromegaly (ACRO) and 27 healthy 
controls. 
 ACRO (n = 27) Controls (n = 27) P valuea
Age (years) 48 ± 5 50 ± 8 0.57
Males/females 11/16 11/16
BMI (kg/m2) 28 ± 4 27 ± 5 0.87
GH (µg/L) 1.3 ± 1.5 1.4 ± 2 0.89
IGF1 (ng/mL) 177 ± 68 148 ± 33 0.13
IGF1SDS 0.9 ± 1 0.3 ± 0.7 0.10
Bone markers
 Serum calcium (mg/dL) 9.6 ± 0.5 9 ± 1.6 0.25
 25(OH)D (ng/mL) 66 ± 27 64 ± 35 0.79
 Serum PTH (pg/mL) 38 ± 19 36 ± 12 0.88
 Osteocalcin (ng/mL) 17 ± 8 19 ± 6 0.42
 Total P1NP (ng/mL) 45 ± 22 54 ± 23 0.17
 CTx (ng/mL) 0.35 ± 0.18 0.39 ± 0.18 0.51
 Osteoprotegerin (pmol/L) 4.6 ± 1.5 3.9 ± 0.8 0.047
 DKK1 (pmol/L) 35 ± 15 25 ± 14 0.011
 SOST (pmol/L) 39 ± 6 38 ± 5 0.92
DXA parameters
 Lumbar T-score −1.2 ± 1.1 −0.8 ± 1.3 0.30
 Lumbar BMD 0.91 ± 0.13 0.94 ± 0.12 0.54
 Femur T-score −0.6 ± 0.98 −0.36 ± 1 0.39
 Femoral neck aBMD 0.90 ± 0.13 0.94 ± 0.14 0.39
 Total hip aBMD 0.81 ± 0.11 0.81 ± 0.12 0.97
TBS 1.26 ± 0.13 1.3 ± 0.14 0.14
QCT parameters
 Lumbar spine-vBMD 106 ± 39 129 ± 30 0.040
 Total hip-vBMD
  Trabecular 128 ± 21 141 ± 24 0.095
  Cortical 831 ± 57 883 ± 65 0.014
 Femoral neck-vBMD
  Trabecular 132 ± 28 147 ± 27 0.11
  Cortical 817 ± 90 902 ± 159 0.037
 Trochanteric-vBMD
  Trabecular 128 ± 19 137 ± 20 0.85
  Cortical 742 (86) 848 (204) 0.006
 Intertrochanteric-vBMD
  Trabecular 127 ± 25 143 ± 28 0.074
  Cortical 855 ± 62 882 ± 38 0.34
Biomechanical parameters
 CSA total 9.9 ± 2 8 ± 2 0.031
 ACT 0.34 ± 0.06 0.32 ± 0.88 0.29
 BR 5.2 ± 0.9 5.4 ± 2 0.59
aStudent’s t-test comparing patients with acromegaly vs healthy controls. 
25(OH)D, 25-hydroxyvitamin D; ACT (average cortical thickness) is expressed as cm; BMI, body mass index; BR, buckling ratio is unitless; CSA, 
cross-sectional area is expressed as cm2; variables are expressed as mean (±s.d.) or median (interquartile range) depending upon the distribution; 
CTx, carboxy-terminal collagen crosslinks; DKK1, Dickkopf-related protein 1; DXA, dual-energy X-ray absorptiometry; IGF-1, insulin-like growth factor-I; 
P1NP, type 1 amino-terminal propeptide; PTH, parathyroid hormone; QCT, quantitative computed tomography; SOST, sclerostin; TBS, trabecular bone 
score; vBMD, (volumetric bone mineral density) is expressed as mg/cm3. Statistically significant differences (P<0.05) are marked in bold. 
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-18-0482
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
E Valassi et al. miRNAs and bone in 
acromegaly
458:1
age-, sex- and BMI-matched controls. Moreover, we have 
found independent relationships between parameters of 
bone status and both miR-103a-3p and miR-660-5p levels 
that are exclusive for ACRO patients.
As a matter of fact, patients with active ACRO present 
with a disproportionate increase in bone turnover, 
especially resorption, reduced spine and femoral 
vBMD at both trabecular and cortical compartment, 
altered trabecular microstructure and elevated fracture 
risk at lumbar spine (6, 7, 8, 30). After remission of 
chronic GH/IGF-I increase, patients with controlled 
ACRO maintain long-lasting impairment of trabecular 
microarchitecture, which is associated with persistently 
increased risk of vertebral fractures regardless of aBMD 
(6, 7, 8). Interestingly, recent evidence suggests that the 
cortical compartment is also affected in ACRO patients 
with fragility vertebral fractures even long term after 
biochemical control (7, 9, 31, 32).
Mechanisms underlying the detrimental effects of 
GH/IGF-I excess on bone structure are multifactorial 
and still to be entirely elucidated (1). The interaction 
of GH/IGF-I with the RANK-L/OPG system may 
play a role in the regulation of bone metabolism. In 
particular, it has been suggested that IGF-I may enhance 
osteoclastogenesis via stimulation of the RANK-L, whereas 
GH may attenuate this effect by inducing OPG synthesis 
(33). Of note, we have found that OPG levels are greater 
in controlled ACRO patients compared with those in 
Table 2 miRNA expression levels in 27 controlled ACRO patients and 27 sex-, age- and BMI-matched controls. 
miRNA ACRO Controls Fold change P value Q value
hsa-miR-103a-3p 1.1 ± 0.003 0.007 ± 0.004 1.3 <0.001 0.013
hsa-miR-660-5p −2.8 ± 0.005 −2.2 ± 0.07 −1.47 <0.01 0.028
hsa-miR-191-5p −0.74 ± 0.002 −0.009 ± 0.003 1.17 <0.01 0.044
hsa-miR-25-3p 0.21 ± 0.006 0.006 ± 0.007 −1.32 0.041 0.18
hsa-miR-320a 1.02 ± 0.004 1.3 ± 0.007 −1.21 0.085 0.27
hsa-miR-21-5p 2.64 ± 0.002 2.82 ± 0.004 −1.13 0.088 0.27
hsa-miR-29b-3p −4.69 ± 0.006 −0.43 ± 0.007 −1.24 0.099 0.27
hsa-miR-125a-5p −0.26 ± 0.005 −2.87 ± 0.005 1.19 0.12 0.30
hsa-miR-22-3p −0.21 ± 0.006 −1.88 ± 0.008 −1.2 0.17 0.35
hsa-miR-324-5p −0.44 ± 0.008 −4.77 ± 0.008 1.23 0.17 0.35
hsa-miR-29a-3p −2.65 ± 0.006 −2.43 ± 0.007 −1.16 0.23 0.43
hsa-miR-122-5p −1.88 ± 1.02 −0.15 ± 0.13 −0.12 0.25 0.44
hsa-miR-335-3p −7.2 ± 0.009 −0.06 ± 0.009 −0.11 0.39 0.60
hsa-miR-885-5p −0.6 ± 1.1 −6 ± 1.12 −1.19 0.41 0.60
hsa-miR-382-3p −7.3 ± 0.13 −0.79 ± 1.76 0.15 0.47 0.61
hsa-miR-125b-5p −4.1 ± 0.006 −4 ± 0.007 −1.07 0.58 0.71
hsa-miR-10b-5p −3.22 ± 0.006 −3 ± 0.008 −1.07 0.61 0.71
hsa-miR-7-1-3p −0.57 ± 0.007 −5.79 ± 1.12 1.06 0.74 0.79
hsa-miR-99a-5p −4.34 ± 0.008 −4.27 ± 0.008 −1.05 0.75 0.79
hsa-miR-223-3p 4.81 ± 0.004 −4.79 ± 0.006 1 0.93 0.93
 Bold values indicate the miRNAs that passed the false-discovery rate (FDR) for multiple comparisons (Q value <0.05). Values shown are those with a 
nominal P value <0.05 which was obtained using Student’s t-test paired with data normalized by log2 transformation. Q values were calculated as 
estimates of the multiple-testing FDR. ACRO, acromegaly; miRNA, microRNA. 
Table 3 Correlations between miRNA expression and bone markers or bone parameters as assessed by dual-energy 
absorptiometry (DXA) and quantitative computed tomography (QCT) in 27 patients with acromegaly, after adjusting for age, sex, 
BMI and gonadal status. 
hsa-miR-103a-3p hsa-miR-660-5p hsa-miR-25-3p
25(OH)D (ng/mL) r 0.54; P = 0.003 r −0.44; P = 0.022
Osteocalcin (ng/mL) r 0.38; P = 0.047
CTx (ng/mL)
OPG (pmol/L) r −0.41; P = 0.032 r 0.47; P = 0.012 
Trochanteric trabecular vBMD r −0.38; P = 0.047 r 0.38; P = 0.047
Total CSA (cm2) ρ 0.43; P = 0.045
25(OH)D, 25-hydroxyvitaminD; BMD, bone mineral density; CSA, cross-sectional area; CTx, carboxy-terminal collagen crosslinks; OPG, osteoprotegerin; 
P1NP, total procollagen type 1 amino-terminal propetide; TBS, trabecular bone score; vBMD, volumetric bone mineral density. 
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healthy subjects, as a possible compensatory mechanism, 
which counteracts increased bone resorption. Constantin 
et al. reported no change in the RANK-L/OPG ratio after 
surgical control of ACRO as compared with baseline, 
suggesting sustained perturbations of this system despite 
hormone normalization (34). Inour study, miR-103a-3p, 
upregulated in ACRO, was negatively associated with 
OPG and trabecular vBMD at the trochanter. It has 
been recently found that miR-103a, which is expressed 
in both osteoblasts and osteoclasts of postmenopausal 
women, negatively regulates osteoblast differentiation 
and bone formation under mechanical loading, by 
repressing the expression of RUNX2, a key transcriptional 
factor for osteogenesis (27, 35). Valenti et al. described a 
RUNX2 overexpression in MSCs during both the active 
and controlled phase of the disease, which was also 
associated with bone quality impairment, as assessed 
through histomorphometric analyses (36). As a matter 
of fact, both RUNX2 deletion and overexpression led 
to impaired bone formation (37, 38). However, Belaya 
et al. reported unchanged expression of RUNX2 in bone 
samples of active ACRO patients, whereas no studies 
have been published thus far on controlled ACRO 
patients (22). It could be speculated that, in controlled 
patients, miR-103a participates in this complex network 
of signals modulating both osteoclastogenesis and 
osteoblastogenesis, also through the regulation of the 
RANK-L/OPG system.
In contrast with miR-103a-3p, the miR-660-5p, 
downregulated in ACRO patients, positively correlated 
with both trabecular vBMD at trochanter and OPG. As 
far as we know, there is no information about the miR-
660-5p’s role in bone tissue, and the present study shows, 
for the first time, an association between this miRNA and 
bone.
miR-103a-3p and miR-660-5p appear to have 
an opposite relationship with parameters of bone 
metabolism, including vitamin D. While 1,25 (OH)2D 
levels have been described as normal or high during the 
active phase of the disease, its levels, as well as those 
of 25(OH)D, did not change after control of GH/IGF-I 
excess (34, 39, 40).
Our results suggest that miR-103a-3p and miR-660-5p 
could be potential markers of bone status and could predict 
the persistence of bone abnormalities in controlled ACRO 
patients. Noteworthy, these miRs were related to bone 
measurements even in healthy subjects. In particular, 
there was an opposite relationship between miR and TBS, 
while miR-103a-3p was positively associated with CTx, 
a marker of bone resorption. Such findings strengthen 
the hypothesis that miR-103a-3p and miR-660-5p play 
a physiological role in regulating bone homeostasis and, 
therefore, may represent potential signatures for bone 
deterioration under pathological conditions like GH/IGF-I 
excess.
We have also found that miR-191-5p was upregulated 
in our patients. However, we did not detect any 
relationships between its levels and any of the bone 
parameters we measured. We are not aware of any putative 
role of this miRNAs in bone regulation and, therefore, 
we hypothesize that this finding may be independent of 
skeletal health.
As we previously described, DKK1 levels were higher 
in ACRO patients as compared with controls, but no 
relationship was found between this Wnt signaling 
inhibitor and any of the miRNAs analyzed (41).
Limitations of our study include small sample size and 
relative heterogeneity of our population. In particular, 
19% of patients were in pharmacological remission and 
26% received radiotherapy. It is currently not known 
whether pharmacological treatment of ACRO may cause 
independent skeletal actions on bone or interfere with 
miRNA expression (42). Nevertheless, none of the miRNAs 
described here have been reported as differentially 
expressed in GH-secreting pituitary adenomas from 
patients who are responders vs nonresponders to 
somatostatin analogs (28). Ten of our patients had also 
undergone radiotherapy previously, but Biermasz et  al. 
demonstrated that previous pituitary irradiation was not 
associated with alteration of lumbar spine BMD in ACRO 
Table 4 Correlations between miRNA expression and bone markers or bone parameters (as assessed by DXA or QCT) in 27 
healthy subjects after adjusting for sex, age, BMI and gonadal status. 
hsa-miR-103a-3p hsa-miR-660-5p hsa-miR-25-3p
CTx (ng/mL) r 0.45; P = 0.017
Lumbar spine aBMD r −0.43; P = 0.030
TBS r 0.51; P = 0.006 r −0.43; P = 0.023
aBMD, areal bone mineral density; BMD, bone mineral density; CTx, carboxy-terminal collagen crosslinks; OPG, osteoprotegerin; SOST, sclerostin; TBS, 
trabecular bone score; vBMD, volumetric bone mineral density. 
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patients in remission (43). Similarly, we could not assess 
the impact of comorbidities on miRNA expression in 
our patients. Another limitation of this study is its cross-
sectional design, which prevents from inferring causality 
from our data. Lack of information on vertebral fractures 
as well as lack of a group with active acromegaly are the 
other limitations of this study.
Since the source of the miRNAs in serum is currently 
unknown, we cannot exclude that alterations of miRNA 
expression may reflect specific actions in other tissues. 
miRNAs are ubiquitous modulators controlling multiple 
patterns of gene expression and, therefore, may play a 
pathogenic role in several tissues and/or may be markers 
of more than one ACRO-related complication.
Indeed, ACRO is a multisystemic disease, which 
also seems to be associated with an elevated risk of 
malignancies (44). It is intriguing to speculate that miR-
103a-3p, miR-660-5p and miR-191-5p, which have been 
related to oncogenesis both in vitro and in vivo, may also 
be involved in the occurrence of tumors in ACRO patients 
(45, 46, 47, 48, 49, 50).
Furthermore, associations of miRNAs and bone 
parameters remained significant after adjusting for the 
gonadal status, suggesting that previous exposure to GH/
IGF-I excess is the main determinant of bone impairment 
in patients with controlled ACRO, thus counteracting 
the negative effect of concomitant hypogonadism. 
Indeed, Madeira et  al. found deteriorated trabecular 
microarchitecture at both the distal radius and distal tibia, 
as assessed by high-resolution peripheral QCT (HR-pQCT), 
in eugonadal patients with controlled ACRO, as compared 
with their hypogonadal counterpart (6). Similarly, 
Godang et  al. showed that TBS was reduced in ACRO 
eugonadal men after 1 year of hormone excess correction, 
but not in hypogonadal subjects (39). Moreover, another 
study reported no associations between the gonadal 
status of controlled ACRO patients and trabecular vBMD 
measurements across the proximal femur and also showed 
that controlled ACRO with normal gonadal function had 
lower vBMD at both total hip and intertrochanter as 
compared with controls (8).
In conclusion, we have described that some miRNAs 
are differentially expressed in the serum of ACRO 
patients as compared with controls and are associated 
with both biochemical and structural parameters of bone 
metabolism. In particular, our data, which need to be 
confirmed in larger studies, suggest that miR-103a-3p and 
miR-660-5p may be promising biomarkers to evaluate the 
presence of bone disease in GH/IGF-I excess and assess the 
persistence of bone impairment even after biochemical 
control has been reached.
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